REAL-WORLD TREATMENT PATTERNS, HEALTHCARE RESOURCE UTILIZATION (HCRU) AND CLINICAL OUTCOMES OF PATIENTS WITH EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (ES-SCLC) IN ALBERTA, CANADA

被引：0
|
作者：
Suri, G. [1 ]
Boyne, D. J. [2 ]
Caveen, M. [3 ]
Mak, D. [3 ]
Takundwa, R. [4 ]
Wani, R. J. [3 ]
Cheung, W. [2 ]
机构：
[1] Amgen Ltd, Uxbridge, England
[2] Oncol Outcomes, Calgary, AB, Canada
[3] Amgen Canada Inc, Mississauga, ON, Canada
[4] Amgen Ltd, Uxbridge, England
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO37
引用
收藏
页码：S23 / S23
页数：1
相关论文
共 50 条
  • [21] Prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer (ES-SCLC): A tertiary cancer centre experience
    Srivastava, A.
    Shelly, K.
    Lin, F.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S46 - S47
  • [22] Real-world predictors of survival in patients with extensive-stage small-cell lung cancer in Manitoba, Canada: a retrospective cohort study
    Dawe, David E.
    Rittberg, Rebekah
    Syed, Iqra
    Shanahan, Mary Kate
    Moldaver, Daniel
    Bucher, Oliver
    Galloway, Katie
    Reynolds, Kayla
    Paul, James T.
    Harlos, Craig
    Kim, Julian O.
    Banerji, Shantanu
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [23] Myeloprotection effects of trilaciclib in Chinese patients with extensive stage small cell lung cancer (ES-SCLC) receiving chemotherapy-a real-world study
    Chen, Yongxing
    Meng, Chong
    Liu, Lirong
    Liu, Kai
    Chen, Tao
    Yang, Chen
    JOURNAL OF THORACIC DISEASE, 2024, 16 (11)
  • [24] UPDATED PFS ANALYSIS OF TORIPALIMAB WITH ANLOTINIB AND CHEMOTHERAPY AS FIRST-LINE THERAPY IN PATIENTS WITH EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (ES-SCLC)
    Luo, Hao
    Jian, Dan
    Feng, Yan
    Zhong, Li
    Chen, Qian
    Guan, Wei
    Zhang, Shiheng
    Luo, Jiamin
    Yang, Xueqin
    Gong, Kan
    Xiong, Yanli
    Li, Mengxia
    Xu, Mingfang
    Pu, Yu
    Zhao, Liang
    Qian, Chengyuan
    Dai, Nan
    Wang, Dong
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A490 - A490
  • [25] REAL-WORLD TREATMENT DURATION OF ATEZOLIZUMAB plus CARBOPLATIN plus ETOPOSIDE AMONG OLDER PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) AND THE IMPACT OF PERFORMANCE STATUS AND BRAIN METASTASES
    Albarmawi, Husam
    Robinson, Scott
    Dietz, Kevin
    Norris, Kris
    Paranthaman, Nindhana
    Ogale, Sarika
    Schwartz, Taylor
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A830 - A830
  • [26] Treating patients with platinum-sensitive extensive-stage small-cell lung cancer in a real-world setting
    Sands, Jacob
    Subramanian, Janakiraman
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [27] Prognostic impact of Neutrophil-to-Lymphocyte Ratio (NLR) For Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
    Ishihara, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S684 - S685
  • [28] Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapy
    Valette, Clarisse Audigier
    Filleron, Thomas
    Debieuvre, Didier
    Lena, Herve
    Perol, Maurice
    Chouaid, Christos
    Simon, Gaetane
    Quantin, Xavier
    Girard, Nicolas
    RESPIRATORY MEDICINE AND RESEARCH, 2023, 84
  • [29] Treatment patterns in extensive-stage small cell lung cancer: A retrospective real-world data study.
    Ganti, Apar Kishor
    Katranji, Kenan
    Seal, Brian S.
    Brannman, Lance
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (29)
  • [30] Amrubicin and carboplatin with pegfilgrastim in patients with extensive-stage small-cell lung cancer (ES-SCLC): A phase II study of the Sarah Cannon Research Institute (SCRI).
    Shipley, Dianna
    Hainsworth, John D.
    Mekhail, Tarek
    Zubkus, John D.
    Flora, Douglas B.
    Daniel, Davey B.
    Waterhouse, David Michael
    Gravenor, Donald
    Burris, Howard A.
    Greco, Frank A.
    Spigel, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345